Pink Sheet reporter and editors discuss the FTC’s challenges of Orange Book patents (:35), DTC promotion practices as part of acquisition due diligence (12:39), and how Intarcia’s advisory committee decision appeal could play out (19:06). More On These Topics From The Pink Sheet In Swift Challenge To Orange Book Patent Listings, Federal Trade Commission Fills FDA Ministerial Gap: https://pink.citeline.com/PS149316/In-Swift-Challenge-To-Orange-Book-Patent-Listings-Federal-Trade-Commission-Fills-FDA-Ministerial-Gap Rx Ad/Promo Practices Should Be Part Of Acquisition Due Diligence, DoJ Official Says: https://pink.citeline.com/PS149309/Rx-AdPromo-Practices-Should-Be-Part-Of-Acquisition-Due-Diligence-DoJ-Official-Says Intarcia Appeals Advisory Committee On Diabetes Drug-Device Combo, Claiming ‘Misrepresentation’: https://pink.citeline.com/PS149311/Intarcia-Appeals-Advisory-Committee-On-Diabetes-DrugDevice-Combo-Claiming-Misrepresentation

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related